U.S. Markets closed

What Solid Biosciences' First Failure Means for Sarepta Therapeutics

Cory Renauer, The Motley Fool

Sarepta Therapeutics(NASDAQ: SRPT) stock enjoyed a nice bounce after a disappointing first look at an experimental gene therapy from a potential competitor, Solid Biosciences (NASDAQ: SLDB). Although Solid's stock price tanked, the start-up biotech's muscular dystrophy program is a long way from washed up.

Initial results from Solid's lead candidate, SGT-001, were far from encouraging, but it's still too soon for Sarepta investors to assume Solid's similar approach isn't a threat anymore. Here's what you need to know about both clinical-stage programs.

A doctor in a hallway with his hand over one eye -- as if he made a mistake and is just realizing it.

Image source: Getty Images.

Important similarities

Boys who inherit Duchenne muscular dystrophy can't produce enough dystrophin to protect their muscle tissue. Dystrophin is a relatively simple structural protein, but the complete gene is way too long to fit inside any delivery vehicle.

Solid Biosciences' gene therapy candidate, SGT-001, and another from Sarepta Therapeutics called AAVrh74.MHCK7.micro-dystrophin use a clever trick to get muscle cells to produce dystrophin on their own. Both deliver a relatively tiny micro-dystrophin gene to muscle cells that allows them to produce the protective scaffolding they need.

About mice and men

Grizzled biotech veterans know that successful results from trials with mice are just the first steps on the path to beginning trials with real patients. Solid Biosciences investors recently found out the hard way how dangerous it can be to make assumptions based on preclinical success. 

Solid's lead candidate, SGT-001, produced striking improvements to the amount of functional dystrophin produced in the muscles of test mice at a dosage of 50 trillion vector genomes per kilogram of body weight (vg/kg). That might seem like a lot, but it wasn't enough to help the first three Duchenne muscular dystrophy (DMD) patients the same way it helped mice. 

The best muscle biopsy result for patients three months after receiving a single infusion of SGT-001 was from one with micro-dystrophin present in around 10% of fibers, as determined by just one of two tests used. There was a detectable amount among all three patients, but the levels were too small to measure and almost certainly too small to make a difference for the patients.

Doctor taking notes on a clipboard with a nurse in the background.

Image source: Getty Images.

Important differences

The first three boys treated with Sarepta's candidate had micro-dystrophin in 81% of muscle fibers at an assessment 60 days after they received a single dose containing 200 trillion vg/kg, or four times as many copies of micro-dystrophin as patients received in Solid's trial with SGT-001. This might be a simple problem that Solid Biosciences can fix with a larger dosage, or there could be a serious problem with the promoter Solid used.

Transporting bazillions of micro-dystrophin genes from an IV bag and into muscle cells is only half the job for these treatments. Encouraging the right cells to actually do something with the new gene is the hard part. To promote expression of the micro-dystrophin gene, Solid used a muscle-specific promoter called CK8, while Sarepta went with MHCK7.

There really haven't been enough gene therapy trials to know if we should blame Solid's choice of promoter for the dismal results or bad luck with the first dosage strength. We know that Solid Biosciences began working on a next-generation promoter long before it saw any human proof-of-concept data for SGT-001, but that doesn't necessarily mean the company wasn't satisfied with CK8.

Two people in lab coats pointing at a computer screen.

Image source: Getty Images.

What's next

Solid Biosciences set out to test ascending doses of SGT-001 from the beginning. Following dismal results from the first dose, though, management promised to do what it can to shorten the time until the next group of patients receives a higher dose. The company hasn't enrolled any yet, so it's going to be more than a few months before we can be sure that Solid's first experimental gene therapy isn't a threat to Sarepta. 

Last spring, Pfizer (NYSE: PFE) began the first clinical trial with a mini-dystrophin candidate for DMD patients called PF-06939926 that work the same way as Sarepta's and Solid's respective candidates. Pfizer will present results from an interim assessment in the first half of 2019, which could take the shine off Sarepta's program.

Recent guidance from the Food and Drug Administration (FDA) suggests the agency might be willing to grant Sarepta's treatment a speedy approval based on biomarkers that suggest the treatment works instead of waiting years to measure different rates of mobility loss. The first four patients showed micro-dystrophin expression in 81% of muscle fibers, and circulating levels of creatine kinase, an enzyme that signals muscle damage, fell 78% from baseline.

If the FDA is willing to approve a new DMD therapy based on efficacy signals instead of waiting years to measure outcomes, Sarepta's chances of a speedy approval seem pretty good. If incoming results fall in line with the first few patients, its micro-dystrophin candidate could start adding nine figures to Sarepta's top line in a few short years.

More From The Motley Fool

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

  • Politics
    Bloomberg

    Warren Responds to ‘Angry Dad’ Over Student Loan Plan

    In a clip shared on an anonymous pro-Trump Twitter account Tuesday and amplified by conservative media, an unnamed man tells Warren that he gave up vacations and saved money for his daughter's education so that she wouldn't have debt. Asked about the clip in an interview on “CBS This Morning,” Warren responded that younger Americans are getting “crushed” by student loan debt, which is roughly $1.5 trillion.

  • One of the most successful stock-market investors says these 3 events ‘would definitely trigger a bear market’
    Business
    MarketWatch

    One of the most successful stock-market investors says these 3 events ‘would definitely trigger a bear market’

    Stanley Druckenmiller, one of Wall Street's most successful investors, acknowledges that the markets are riding high and that investors may be able to finally breathe freely in the short term after a number of shocks, but says investors should be wary of three events that could knock assets into a bear market. One of the reasons I'm pretty sanguine right now is I think we're close enough to the election, at least we can breathe for a few months,” he told Bloomberg Television during a recent interview. But there are a trio of situations that could upend that optimism — and perhaps permanently.

  • ‘Kids that don’t fail are normally frugal.' Wealth advisers say Meghan and Harry’s lifestyle already raises red flags
    News
    MarketWatch

    ‘Kids that don’t fail are normally frugal.' Wealth advisers say Meghan and Harry’s lifestyle already raises red flags

    Meghan and Harry Windsor aren't the first people to try to quit the safety of a rich family and try to go it alone, and they won't be the last. Chief among them: Reports that the couple is looking to buy a mansion in Vancouver on the market for $36 million Canadian dollars ($27 million in U.S. dollars), already dubbed a “Megha-Mansion” by the British press. “That is a red flag,” writes Elizabeth Windisch, a financial planner at Aspen Wealth Management in Centennial, Colo., in an email, “they really couldn't find a nice, secure home for, say, $15 million.” Others agree.

  • Business
    U.S.News & World Report

    7 Best Vanguard Funds to Buy and Hold

    It offers a five-year average return of 7.23% and an expense ratio of 0.14%. Year-to-date, VASGX has delivered a 23.13% return. VITSX is one of the best Vanguard mutual funds for buy-and-hold investors who want broad exposure to the stock market as a whole.

  • Britain's Prince Charles appears to snub Pence
    World
    Associated Press Videos

    Britain's Prince Charles appears to snub Pence

    Britain's Prince Charles appeared to snub U.S. Vice President Mike Pence on Thursday during his arrival to the World Holocaust Forum event. Jan.

  • Retirement: What Happens If a Spouse Dies?
    Business
    Investopedia

    Retirement: What Happens If a Spouse Dies?

    This form names the person or people who will receive your IRA and in what proportions. You can amend the form at any time, but whoever is on the form upon your death will receive the funds—even if they are an ex-spouse or a disinherited child. "If you name multiple people as beneficiaries of one retirement plan, they all take required minimum distributions (RMDs) based on the life expectancy of the eldest beneficiary (i.e., the person who has to take out the largest distributions).

  • How the stock market has performed during past viral outbreaks, as epidemic locks down 16 Chinese cities
    World
    MarketWatch

    How the stock market has performed during past viral outbreaks, as epidemic locks down 16 Chinese cities

    According to Dow Jones Market Data, the S&P 500 posted a gain of 14.59% after the first occurrence of SARS back in 2002-03, based on the end of month performance for the index in April, 2003. About 12 months after that point, the broad-market benchmark was up 20.76% (see attached table): SARS resulted in a total of about 8,100 people being sickened during the 2003 outbreak, with 774 people dying, according to data from WHO and the Centers for Disease Control and Prevention. Separately, the S&P 500 rose 11.66% in the roughly six months following reports of the 2006 Avian flu virus — a fast-moving pathogen also known as H5N1.

  • Stock Market Dives After CDC Confirms Second U.S. Case Of Deadly China Virus
    Business
    Investor's Business Daily

    Stock Market Dives After CDC Confirms Second U.S. Case Of Deadly China Virus

    Stocks turned red and headed sharply lower after the Centers for Disease Control and Prevention confirmed a second U.S. case of the China coronavirus, putting the Dow Jones Industrial Average on track for a 1.5% weekly loss. The S&P 500 tumbled 1.2%, the Nasdaq dived 1.1% and the Dow Jones industrials sank 0.9% in today's stock action. Small caps tracked by the Russell 2000 shed 1.9%.

  • 3 Top Dividend Stocks with Over 7% Dividend Yield
    Business
    TipRanks

    3 Top Dividend Stocks with Over 7% Dividend Yield

    These profit-sharing payments give investors a steady income stream – even when market gains are sluggish. As an added appeal, there is no upper limit to a dividend's yield. After three Fed rate cuts in 2019, Treasury bonds are down to the 1.5% to 1.75% range – while the average dividend yield among S&P-listed companies is just about 2%.

  • Want to solve the retirement crisis? Invest $7,500 for every baby born in America
    Business
    MarketWatch

    Want to solve the retirement crisis? Invest $7,500 for every baby born in America

    This federal program, which doles out an average monthly benefit of about $1,500, was never meant to be the sole source of retirement income for older Americans. One recent proposal aims to change that. As part of his work with the Stanford Center on Longevity, Ric Edelman, chairman and co-founder of Edelman Financial Services, proposed a new vehicle to generate an additional source of retirement income.

  • AMD earnings: Intel’s data-center surge will be a tough act to follow
    Business
    MarketWatch

    AMD earnings: Intel’s data-center surge will be a tough act to follow

    Advanced Micro Devices Inc.'s sales of server chips may get heightened scrutiny following a surprise jump in data-center sales reported by larger rival Intel Corp. AMD (AMD) shifted the power balance against bigger rival Intel Corp. (INTC) last year as it released its 7-nm “Rome” chips while Intel failed to bring its 10-nm chip to the market. AMD's forceful re-entry into the server business, which had been completely dominated by Intel for many years, was a big part of its turnaround.

  • Tesla earnings: Will results help keep the rally alive?
    Business
    MarketWatch

    Tesla earnings: Will results help keep the rally alive?

    The company will have to convince investors that its fundamentals justify the string of record highs the stock has hit since mid-December. Investors will zero in on Tesla's 2020 sales outlook, said Garrett Nelson, an analyst with CFRA. Generally, we think the recent stock price run-up has greatly raised the bar in terms of expectations and elevated the risk of disappointment,” he said.

  • Tesla will mark the beginning of the end for this bull market, warns Ralph Nader
    Business
    MarketWatch

    Tesla will mark the beginning of the end for this bull market, warns Ralph Nader

    Apparently so, according to consumer advocate and former presidential candidate Ralph Nader, who issued a stark warning this week, not only on the electric-car maker's pricey stock, but on the stock market as a whole. “Deep in debt, selling less than 400,000 vehicles last year and challenged by several competing electric car models in 2020, Tesla's stock valuation stunningly exceeds VW which sold over 10 million vehicles last year,” Nader added in a follow-up tweet. Of course, his stance didn't sit well with Tesla fans.

  • Brad Pitt: 'I'm old'
    News
    Associated Press Videos

    Brad Pitt: 'I'm old'

    As he's presented with the Maltin Modern Masters Award in Santa Barbara, Brad Pitt admits he may have forgotten the first rule of Fight Club, but feels blessed to have the life he's had. Jan.

  • Why this CIO is bullish on two of the most unloved stocks: Boeing and GE
    Business
    Yahoo Finance

    Why this CIO is bullish on two of the most unloved stocks: Boeing and GE

    Meanwhile, the coronavirus outbreak has similarly left markets largely unscathed as stocks continue to hover near their all-time highs. Kramer Capital Research CIO Hilary Kramer considers these events, among others, to be 'non-issues' in a market intent on continuing its climb. Kramer joined The Final Round on Thursday to discuss what risks, if any, could send markets down, and why Boeing (BA) and General Electric (GE) are among her top stock picks.

  • Store closings pile up: With 1,200 closures already announced, retailers face another grim year
    Business
    USA TODAY

    Store closings pile up: With 1,200 closures already announced, retailers face another grim year

    National chains Macy's, J.C. Penney, Papyrus, Express and Pier 1 Imports, as well as other retailers, have collectively announced 1,218 store closures this year, according to global marketing research firm Coresight Research. The fallout comes after a year in which retailers closed more than 9,200 stores, according to Coresight. Those included the liquidation of Payless ShoeSource, Fred's, Gymboree and Charlotte Russe and mass closures by Family Dollar, Forever 21, Charming Charlie, Sears, Kmart, A.C. Moore and GameStop.

  • News
    USA TODAY

    After the wedding, should you marry your money in a joint account? Here are 3 approaches.

    All in It Together “In this model, couples bring all of their assets and liabilities together,” Shekar says, which means joint bank accounts held in both partners' names and accessible to both. When Maureen Wright married her husband, Patrick, a year and a half ago, they immediately decided to merge their finances into one checking, one savings and one joint investment account – just like their parents did. To Wright, who works as a financial adviser, the advantages of banking jointly included built-in accountability, transparency and simplicity.

  • Business
    Barrons.com

    Stocks Catch a Cold After Fed Stops Expanding Its Balance Sheet

    In addition to last year's three one-quarter percentage-point short-term rate cuts, the central bank has expanded its balance sheet by over $300 billion since September, when ructions in the repurchase-agreement market led it to inject liquidity. Since then, U.S. stocks' value has jumped by more than $3 trillion. The Fed insists that its operations don't constitute quantitative easing, as it calls its purchases of long-term securities intended to boost stock and bond prices.

  • Boeing 737 Max Could Get FAA OK Soon But Earnings Promise Huge Sticker Shock
    Business
    Investor's Business Daily

    Boeing 737 Max Could Get FAA OK Soon But Earnings Promise Huge Sticker Shock

    The timeline for resuming production on the Boeing 737 Max and returning it to service will be big topics when the company reports earnings Wednesday. Analysts see Boeing's earnings falling 68.4% to $1.73 per share with revenue down 23.5% to $21.67 billion. "As we noted in our 4Q19 earnings preview, we are expecting Boeing's upcoming results to be 'an absolute disaster,' and that now looks guaranteed," wrote Vertical Research analysts Robert Stallard and Karl Oehlschlaeger in a note.

  • 5G to IoT: 3 Long-Term Growth Stocks in the Tech Sector
    Business
    GuruFocus.com

    5G to IoT: 3 Long-Term Growth Stocks in the Tech Sector

    SWKS 30-Year Financial Data The intrinsic value of SWKS Peter Lynch Chart of SWKS As the world becomes increasingly connected on the foundation of 5G, companies whose products are geared towards the so-called Internet of Things (IoT) are more likely to see stronger growth than their competitors. Smartphones won't be the next big thing forever, so if you are looking for long-term 5G growth potential, smartphone stocks may not necessarily be your best bet (though their potential in the short term is undeniable). Instead, the companies that will be involved in the 5G rollout and also stand to benefit from IoT technology might be better investments.

  • Save $1,000 a year. Retire with millions
    Business
    MarketWatch

    Save $1,000 a year. Retire with millions

    At that point, after 48 years, our investor would have made total contributions of $104,408. That's the first of two “little-things-mean-a-lot” lessons here: Small contributions can grow to become mighty sums. Now to get back to that tiny (and necessary) 0.1% mutual fund expense ratio: It would have paid the mutual fund about $70,000 over the years.

  • Head of U.S.’ largest bank says central banks are fueling a sovereign debt bubble, negative-rates won’t ‘end well’
    Business
    MarketWatch

    Head of U.S.’ largest bank says central banks are fueling a sovereign debt bubble, negative-rates won’t ‘end well’

    Jamie Dimon doesn't have much positive to say about negative interest rates in Europe and Japan or public policy in the United States during the past decade. The JPMorgan Chase & Co. (JPM) Chairman and CEO blasted the policy of negative interest rates adopted in Europe and Japan during an interview Wednesday with CNBC, while arguing that economic growth in the U.S. could have been nearly double its actual rate if the government policy had been better. Dimon took aim at fiscal and other economic policies in place at the U.S. federal level.

  • Inovio’s stock soars after receiving grant to develop coronavirus vaccine
    Business
    MarketWatch

    Inovio’s stock soars after receiving grant to develop coronavirus vaccine

    As the coronavirus out of China spreads and gets deadlier, shares of health care companies that announce plans to take part in finding a vaccine, or identifying patients with the new strain, have rallied sharply in very active trading. On Thursday, among the bigger coronavirus gainers was Inovio Pharmaceuticals Inc.'s stock (INO) , which ran up 12% to the highest close since May 9. The Pennsylvania-based biotechnology company said early Thursday that it was awarded a grant of up to $9 million by the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for the new strain of coronavirus, 2019-nCoV, which originated in Wuhan, China, and has killed no less than 17 people.

  • Canopy Growth (CGC): Why The Beverage Debacle Is a Big Problem
    Business
    TipRanks

    Canopy Growth (CGC): Why The Beverage Debacle Is a Big Problem

    Beverage Debacle Canopy Growth shocked the market last week by admitting their cannabis-infused beverages were not ready to scale for the market. The news is surprising considering the company is already a month into the legalization of Cannabis 2.0 products such as edibles and beverages. New CEO David Klein suggests the time period since Canopy Growth obtained Health Canada license in late November 2019 wasn't enough time to work out the kinks with THC in a brand new beverage facility.

  • PG&E Probation Judge Threatens to Restrict Manager Bonuses
    Business
    Bloomberg

    PG&E Probation Judge Threatens to Restrict Manager Bonuses

    As PG&E struggles to prove it can operate safely after a series of devastating wildfires blamed on its equipment, U.S. District Judge William Alsup threatened in a filing Friday to tie incentive pay “exclusively” to meeting goals for fire mitigation and other safety issues. In response, Alsup has said he may require PG&E to hire and train more crews to inspect and cut trees to come into compliance with state requirements. Alsup is overseeing PG&E's criminal probation after the utility was convicted in 2016 of violating gas-pipeline safety standards and obstructing a federal investigation.